Figure 6. G9 cooperates with inhibition of mutant BRAF to inhibit tumor growth in vivo.

(A) Vemurafenib, G9 and combination treatment in in vitro and in vivo in melanoma cells. A375 BRAF mutant cells were treated with vemurafenib, G9, or the combination before cell lysates were examined for indicated proteins. (B) Images of colony growth (detected by crystal violet staining) in BRAF-mutant A375 cells, which were treated with vemurafenib, G9, or the combination for 21 days (fresh drug was added every three days) in standard 2D culture. (C) NSG mice with A375 BRAF mutant melanoma tumors were treated with 25 mg/kg vemurafenib daily, 15 mg/kg G9 every other day, or both for 3 weeks by i.p injection, and tumor dimensions were measured. For each treatment four individual mice were used. (D) Animal weight was recorded through the treatment interval. Actin served as a loading control wherever necessary. ^*** P < 0.001. The statistically significant values were measured by Mann–Whitney U test for comparisons of control vs G9 (p value 0.1308), control vs vemurafenib (p value 0.0097), and control vs combination (G9+vemurafenib) (p value < 0.0001).